Litcius/Paper detail

Pegcetacoplan versus eculizumab in patients with paroxysmal nocturnal haemoglobinuria (PEGASUS): 48-week follow-up of a randomised, open-label, phase 3, active-comparator, controlled trial

Régis Peffault de Latour, Jeff Szer, Ilene C. Weitz, Alexander Röth, Britta Höchsmann, Jens Panse, Kensuke Usuki, Morag Griffin, Jean‐Jacques Kiladjian, Carlos M. de Castro, Hisakazu Nishimori, Temitayo Ajayi, Mohammed Al-Adhami, Pascal Deschatelets, Cedric Francois, F Grossi, Antonio M. Risitano, Peter Hillmen

2022The Lancet Haematology71 citationsDOI

Topics & Concepts

MedicineEculizumabClinical endpointInternal medicineRegimenOpen labelClinical trialRandomized controlled trialAntibodyImmunologyComplement systemComplement system in diseasesBlood groups and transfusionPlatelet Disorders and Treatments